Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5JR2

Crystal structure of the EphA4 LBD in complex with APYd3 peptide inhibitor

5JR2 の概要
エントリーDOI10.2210/pdb5jr2/pdb
分子名称Ephrin type-A receptor 4, APYd3 peptide, HEXANE-1,6-DIOL, ... (5 entities in total)
機能のキーワードreceptor tyrosine kinase, peptide inhibitor, ephrin, als, transferase-inhibitor complex, transferase/inhibitor
由来する生物種Homo sapiens (Human)
詳細
タンパク質・核酸の鎖数8
化学式量合計89020.84
構造登録者
Lechtenberg, B.C.,Olson, E.J.,Pasquale, E.B.,Dawson, P.E.,Riedl, S.J. (登録日: 2016-05-05, 公開日: 2016-07-06, 最終更新日: 2024-10-16)
主引用文献Olson, E.J.,Lechtenberg, B.C.,Zhao, C.,Rubio de la Torre, E.,Lamberto, I.,Riedl, S.J.,Dawson, P.E.,Pasquale, E.B.
Modifications of a Nanomolar Cyclic Peptide Antagonist for the EphA4 Receptor To Achieve High Plasma Stability.
Acs Med.Chem.Lett., 7:841-846, 2016
Cited by
PubMed Abstract: EphA4 is a receptor tyrosine kinase with a critical role in repulsive axon guidance and synaptic function. However, aberrant EphA4 activity can inhibit neural repair after injury and exacerbate neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer's. We previously identified the cyclic peptide APY-d2 (APYCVYRβASWSC-nh2, containing a disulfide bond) as a potent and selective EphA4 antagonist. However, APY-d2 lacks sufficient plasma stability to be useful for EphA4 inhibition in vivo through peripheral administration. Using structure-activity relationship studies, we show that protecting the peptide N-terminus from proteolytic degradation dramatically increases the persistence of the active peptide in plasma and that a positively charged peptide N-terminus is essential for high EphA4 binding affinity. Among several improved APY-d2 derivatives, the cyclic peptides APY-d3 (βAPYCVYRβASWSC-nh2) and APY-d4 (βAPYCVYRβAEWEC-nh2) combine high stability in plasma and cerebrospinal fluid with slightly enhanced potency. These properties make them valuable research tools and leads toward development of therapeutics for neurological diseases.
PubMed: 27660688
DOI: 10.1021/acsmedchemlett.6b00132
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.75 Å)
構造検証レポート
Validation report summary of 5jr2
検証レポート(詳細版)ダウンロードをダウンロード

246905

件を2025-12-31に公開中

PDB statisticsPDBj update infoContact PDBjnumon